What is PALI's current stock price?

PALI (Palisade Bio, Inc.) is currently trading at $1.95 with a market cap of $338.5M.

What sector is Palisade Bio, Inc. in?

Palisade Bio, Inc. (PALI) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is PALI a good stock to buy?

Analysts have a Buy consensus on PALI with a price target of $1.50. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

PALI Palisade Bio, Inc.

Healthcare

$1.95-2.99%ClosedMarket Cap: $338.5M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

3.21

P/S

0.00

EV/EBITDA

-7.75

DCF Value

$2.39

FCF Yield

-3.7%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-36.8%

ROA

-18.1%

ROIC

-20.7%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-9.6M	$—
Q4 null	$0.00	$-8.9M	$—
FY null	$0.00	$-16.8M	$—
Q3 null	$0.00	$-2.9M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$1.50

Target (Median)

$1.50

Target Range

$1.50 - $1.50

2 Strong Buy5 Buy0 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All

Jones Mitchell Lawrenceofficer: Chief Medical Officer

SellFri Feb 13

Jones Mitchell Lawrenceofficer: Chief Medical Officer

SellFri Feb 13

Finley John Daviddirector, officer: CEO, CFO

SellFri Feb 13

Finley John Daviddirector, officer: CEO, CFO

SellFri Feb 13

Jones Mitchell Lawrenceofficer: Chief Medical Officer

SellWed Feb 11

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.53

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.

Peers